Investors



Stock price graph

Horizon Pharma, Inc. is a specialty pharmaceutical company that has developed and is commercializing products to primary care, orthopedic surgeons and rheumatologists. The Company markets DUEXIS®, RAYOS®/LODOTRA® and VIMOVO® , which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The Company's strategy is to develop, acquire or in-license additional innovative medicines where it can execute a targeted commercial approach among specific target physicians while taking advantage of its commercial strengths and the infrastructure the Company has put in place. 

Contacts:

Investors

Bob De Vaere
Chief Financial Officer
Horizon Pharma, Inc.
520 Lake Cook Road, Suite 520
Deerfield, IL 60015
bd@horizonpharma.com

Media

BiotechComm
E. Blair Clark-Schoeb
(917) 432-9275
blair@biotechcomm.com

View all   RSSRecent Releases

Horizon Pharma Announces U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering VIMOVO(R) (naproxen / esomeprazole) Delayed Release Tablets

DEERFIELD, IL -- (Marketwired) -- 08/13/14 -- Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that POZEN Inc. (NASDAQ: POZN), has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application number 14/045,156 entitled "Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs" that covers Horizon and POZEN'S U.S. approved product VIMOVO® (naproxen / esomeprazole magnesium) delayed release tablets. "The claims included in this Notice of Allowance continue to expand the strength of the VIMOVO patent estat...

Read more »

Horizon Pharma Announces Effectiveness of S-4 Registration Statement for Acquisition of Vidara Therapeutics International Public Company Limited

DEERFIELD, IL -- (Marketwired) -- 08/08/14 -- Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that the S-4 registration statement filed by Vidara Therapeutics International Public Limited Company ("Vidara") with the Securities and Exchange Commission on June 26, 2014, as amended on July 28, 2014 and August 6, 2014 regarding the proposed acquisition of Vidara through a reverse merger with Horizon Pharma was declared effective by the SEC on August 7, 2014. The Company also announced that Horizon has scheduled a special meeting of its stockholders on Thursday, September 18, 2...

Read more »

Horizon Pharma Reports Second Quarter 2014 Financial Results and Provides Business Update

DEERFIELD, IL -- (Marketwired) -- 08/07/14 -- Horizon Pharma, Inc. (NASDAQ: HZNP) today provided an update on the Company's business and announced financial results for the second quarter ended June 30, 2014. Quarterly Financial Highlights Total net sales of $66.1 million versus $11.1 million in second quarter of 2013 Adjusted EBITDA of $23.8 million Adjusted non-GAAP net income of $20.7 million, or $0.21 non-GAAP diluted earnings per share Cash and cash equivalents of $128.9 million at June...

Read more »

Horizon Pharma Announces the U.S. Patent and Trademark Office Issuance of Additional Notices of Allowance With Claims Covering VIMOVO(R) (Naproxen / Esomeprazole) Delayed Release Tablets

DEERFIELD, IL -- (Marketwired) -- 08/05/14 -- Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that POZEN Inc. (NASDAQ: POZN) has received two Notices of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application numbers 14/231,971, and 14/244,471, entitled "Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs" that cover Horizon and POZEN'S U.S. approved product VIMOVO® (naproxen / esomeprazole magnesium) delayed release tablets. "The claims included in these Notices of Allowance further bolster the already robust VI...

Read more »

Horizon Pharma to Host Conference Call and Webcast to Discuss Second Quarter 2014 Financial Results on August 7, 2014

DEERFIELD, IL -- (Marketwired) -- 07/29/14 -- Horizon Pharma, Inc. (NASDAQ: HZNP) announced today that its second quarter 2014 financial results will be released on Thursday, August 7, 2014. Following the announcement, Horizon's management will host a live conference call and webcast at 8:00 am Eastern Time to review the Company's financial and operating results and provide a general business update. The live webcast and a replay may be accessed by visiting Horizon's website at http://ir.horizon-pharma.com. Please connect to the Company's website at least 15 minutes prior to t...

Read more »